Literature DB >> 25582385

Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis.

Paula Laranjeira1, Raquel Rodrigues2, Tiago Carvalheiro3, Conceição Constanço4, Helena Vitória5, Sergio Matarraz6, Hélder Trindade7, Alberto Órfão8, Artur Paiva9.   

Abstract

Erythroid dysplasia is a common feature of myelodysplastic syndromes (MDS). Currently available information about the immunophenotypic features of normal and dysplastic erythropoiesis is scarce and restricted to relatively few markers. Here we studied the expression of CD117, CD35 and CD44 throughout the normal (n=16) and dysplastic (n=48) bone marrow erythroid maturation. CD35 emerged as an early marker of CD34(+) erythroid-committed precursors, which is expressed before CD105 and remains positive thereafter. MDS patients (with and without morphologic dyserythropoiesis) displayed overall increased expression of CD44, associated with slight alterations on CD35 expression, suggesting that phenotypic alterations in MDS may precede morphologic dysplasia. In turn, MDS patients with anemia showed increased expression of CD117.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD117; CD35; CD44; Erythroid maturation; Erythroid precursor; Myelodysplastic syndrome

Mesh:

Substances:

Year:  2014        PMID: 25582385     DOI: 10.1016/j.leukres.2014.12.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.

Authors:  Justin Sperlazza; Mohamed Rahmani; Jason Beckta; Mandy Aust; Elisa Hawkins; Shou Zhen Wang; Sheng Zu Zhu; Shreya Podder; Catherine Dumur; Kellie Archer; Steven Grant; Gordon D Ginder
Journal:  Blood       Date:  2015-08-11       Impact factor: 22.113

4.  A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer".

Authors:  Ana Aires; Maria Dos Anjos Teixeira; Catarina Lau; Cláudia Moreira; Ana Spínola; Alexandra Mota; Inês Freitas; Jorge Coutinho; Margarida Lima
Journal:  BMC Hematol       Date:  2018-03-13

5.  Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.

Authors:  Benjamin N Ostendorf; Eva Flenner; Anne Flörcken; Jörg Westermann
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

6.  A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.

Authors:  Paula Laranjeira; Tiago Rodrigues; Ana Silva; Pedro Barbosa; Teresa Reis; Cristiana Lopes; Aryane Pinho; Sandra Silva; Isabel Silva; Anabela Carvalho; Vânia Pacheco; Fernando Rodrigues; Lucília Araújo; Isabel Antunes; Artur Paiva
Journal:  Clin Exp Med       Date:  2022-02-21       Impact factor: 3.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.